These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34393717)

  • 1. N-Terminally Truncated and Pyroglutamate-Modified Aβ Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer's Disease.
    Domingo G; Benussi L; Saraceno C; Bertuzzi M; Nicsanu R; Longobardi A; Bellini S; Cagnotto A; Salmona M; Binetti G; Ghidoni R
    Front Neurosci; 2021; 15():708119. PubMed ID: 34393717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Effect on Neurodegeneration by N-Truncated Aβ
    Lopez-Noguerola JS; Giessen NME; Ueberück M; Meißner JN; Pelgrim CE; Adams J; Wirths O; Bouter Y; Bayer TA
    Front Aging Neurosci; 2018; 10():64. PubMed ID: 29568268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody.
    Antonios G; Saiepour N; Bouter Y; Richard BC; Paetau A; Verkkoniemi-Ahola A; Lannfelt L; Ingelsson M; Kovacs GG; Pillot T; Wirths O; Bayer TA
    Acta Neuropathol Commun; 2013 Sep; 1():56. PubMed ID: 24252153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modification-specific peptide-based immunization approach using CRM197 carrier protein:
    Vingtdeux V; Zhao H; Chandakkar P; Acker CM; Davies P; Marambaud P
    Mol Med; 2017 Jan; 22():841-849. PubMed ID: 27900387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry.
    Portelius E; Lashley T; Westerlund A; Persson R; Fox NC; Blennow K; Revesz T; Zetterberg H
    Neurodegener Dis; 2015; 15(1):50-7. PubMed ID: 25591542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary: Abeta N- Terminal Isoforms: Critical contributors in the course of AD pathophysiology.
    Tekirian TL
    J Alzheimers Dis; 2001 Apr; 3(2):241-248. PubMed ID: 12214065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.
    Perez-Garmendia R; Gevorkian G
    Curr Neuropharmacol; 2013 Sep; 11(5):491-8. PubMed ID: 24403873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct deposition of amyloid-β species in brains with Alzheimer's disease pathology visualized with MALDI imaging mass spectrometry.
    Kakuda N; Miyasaka T; Iwasaki N; Nirasawa T; Wada-Kakuda S; Takahashi-Fujigasaki J; Murayama S; Ihara Y; Ikegawa M
    Acta Neuropathol Commun; 2017 Oct; 5(1):73. PubMed ID: 29037261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of N-terminally truncated pyroglutamate amyloid-β in cholesterol-enriched diet-fed rabbit and AD brain.
    Perez-Garmendia R; Hernandez-Zimbron LF; Morales MA; Luna-Muñoz J; Mena R; Nava-Catorce M; Acero G; Vasilevko V; Viramontes-Pintos A; Cribbs DH; Gevorkian G
    J Alzheimers Dis; 2014; 39(2):441-55. PubMed ID: 24240639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrete molecular dynamics study of oligomer formation by N-terminally truncated amyloid β-protein.
    Meral D; Urbanc B
    J Mol Biol; 2013 Jun; 425(12):2260-75. PubMed ID: 23500806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer's pathophysiology.
    Rostagno A; Cabrera E; Lashley T; Ghiso J
    Transl Neurodegener; 2022 Jun; 11(1):30. PubMed ID: 35641972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.
    Pivtoraiko VN; Abrahamson EE; Leurgans SE; DeKosky ST; Mufson EJ; Ikonomovic MD
    Neurobiol Aging; 2015 Jan; 36(1):12-9. PubMed ID: 25048160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An UHPLC-MS/MS method for simultaneous quantification of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid using micro-elution solid phase extraction.
    Lin PP; Chen WL; Yuan F; Sheng L; Wu YJ; Zhang WW; Li GQ; Xu HR; Li XN
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Dec; 1070():82-91. PubMed ID: 29102244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
    Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
    Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.
    Vanderstichele H; De Meyer G; Andreasen N; Kostanjevecki V; Wallin A; Olsson A; Blennow K; Vanmechelen E
    Clin Chem; 2005 Sep; 51(9):1650-60. PubMed ID: 16020497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer's disease: pyroglutamate amyloid beta.
    Vukicevic M; Fiorini E; Siegert S; Carpintero R; Rincon-Restrepo M; Lopez-Deber P; Piot N; Ayer M; Rentero I; Babolin C; Bravo-Veyrat S; Giriens V; Morici C; Beuzelin M; Gesbert A; Rivot S; Depretti S; Donati P; Streffer J; Pfeifer A; Kosco-Vilbois MH
    Brain Commun; 2022; 4(1):fcac022. PubMed ID: 35479516
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.